(4R,6R)-6-Ethyl-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one | 135677-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (4R,6R)-6-Ethyl-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
• 英文别名: (4R,6R)-6-ethyl-4-hydroxyoxan-2-one
• CAS: 135677-41-7
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: HNJJNCRGYGIAGT-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (3R)-(-)-methyl 3-<(tert-butyldimethylsilyl)oxy>-4-formylbutanoate 在 sodium hydroxide 、 正丁基锂 、 氢氟酸 、 碘 、 三正丁基氢锡 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 25.25h， 生成 (4R,6R)-6-Ethyl-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
  参考文献：
  名称：

  Bennett, Frank; Knight, David W.; Fenton, Garry, Journal of the Chemical Society. Perkin transactions I, 1991, # 6, p. 1543 - 1547

  摘要：

  DOI：

文献信息

• QUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF
  申请人：Shanghai Institute of Pharmaceutical Industry

  公开号：EP2284158A1

  公开（公告）日：2011-02-16

  The present invention discloses a quinoline compound represented by the formula A or pharmaceutically acceptable solvate, optical isomer or polymorph thereof, wherein X is S or O; M is H, Na+, NH4+ or Ca2+; each of R1, R2 and R3 is independently H, halogen, the group represented by formula D or formula E; R is H, halogen, C1∼C4 alkyl or C1∼C4 alkoxy. The present invention also discloses its pharmaceutical composition and the preparation method thereof and application in manufacturing a medicament for inhibiting HMG-CoA reductase or for the treatment and prophylaxis of the diseases which can be treated effectively by inhibiting HMG-CoA reductase. The quinloline compound and pharmaceutical composition thereof of the present invention have an excellent lipid reduction effect in vivo and can be applied for treatment of a hyperlipidemia-related disease.

  本发明公开了一种由式 A 或其药学上可接受的溶解物、光学异构体或多晶型代表的喹啉化合物、 其中 X 是 S 或 O；M 是 H、Na+、NH4+ 或 Ca2+；R1、R2 和 R3 各自独立地是 H、卤素、式 D 或式 E 所代表的基团；R 是 H、卤素、C1∼C4 烷基或 C1∼C4 烷氧基。 本发明还公开了其药物组合物及其制备方法，以及在制造抑制 HMG-CoA 还原酶的药物或治疗和预防通过抑制 HMG-CoA 还原酶可有效治疗的疾病中的应用。本发明的喹啉化合物及其药物组合物在体内具有良好的降脂效果，可用于治疗高脂血症相关疾病。
• DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING
  申请人：Yamauchi Tadakazu

  公开号：US20090233274A1

  公开（公告）日：2009-09-17

  The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like.
• COMPOSITION AND METHOD FOR TREATING CANCER
  申请人：CELLWORKS GROUP, INC.

  公开号：US20160058751A1

  公开（公告）日：2016-03-03

  The present disclosure relates to a pharmaceutical composition and a kit to treat cancer. The disclosure provides a combination of compounds for use in the treatment of cancer. The disclosure further provides a process of preparing the composition and a method of treating a cancer associated with a RAS mutation or a RAS mutation along with any other mutation.
• LIQUID STATIN FORMULATION
  申请人：Joiner Peter

  公开号：US20160310463A1

  公开（公告）日：2016-10-27

  The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention.
• US8178077B2
  申请人：——

  公开号：US8178077B2

  公开（公告）日：2012-05-15